Biomaterial Database

[Treatment of progressive chronic polyarthritis with a non-steroidal antirheumatic agent with a long half-life]. 1979

K Pavelka, and A Schusta

73 patients with definite active rheumatoid arthritis were treated with naproxen, 250 mg b.i.d. One month after the start of therapy the patients were examined as to following parameters: spontaneous pain and pain on movement, duration of morning stiffness, fatigue, grip strength, functional joint index, ESR and consumption of analgesics. On statistical analysis a significant improvement of all the parameters, with the exception of ESR was shown, 52 of the 73 patients were very satisfied resp. satisfied with the treatment, whereas the physician evaluated the therapeutic results as very good to good in 49 of the cases. In 50 of the patients the therapy with naproxen, 250 mg b.i.d., was continued for two more months. In most of these cases it was possible to achieve an additional improvement in the parameters evaluated. Unwanted side effects occurred in 7 patients, of which in 4 the treatment had to be discontinued (in two cases because of dyspepsia and once each because of an angioneurotic edema and a recurrence of a peptic ulcer, respectively). The three patients in whose cases therapy was continued suffered from mild gastrointestinal disturbances.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009288	Naproxen	An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.	Aleve,Anaprox,Methoxypropiocin,Naprosin,Naprosyn,Naproxen Sodium,Proxen,Sodium Naproxenate,Synflex,Naproxenate, Sodium,Sodium, Naproxen
D004341	Drug Evaluation	Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.	Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260	Female		Females
D006207	Half-Life	The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.	Halflife,Half Life,Half-Lifes,Halflifes
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172	Arthritis, Rheumatoid	A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	Rheumatoid Arthritis